Abstract:Objectives The great difference in side effects of aprotinin was noted in adult and pediatric fields in recent reports because aprotinin was suspended for safety reasons. The aim of this study is to describe associations between aprotinin using and red blood cells transfusion, renal injury, and mortality in pediatric with cardiac surgery. Methods We retrospectively reviewed a cohort of 507 consecutive children who received a single dose of aprotinin (MarchNovember 2007 before the FDA's decision for withdrawal of aprotinin) and a cohort of 494 consecutive children who did not receive aprotinin or other antifibrinolytic drugs (December 2007August 2008). Results The two groups' demographics were assessed by the Aristotle Basic Complexity (ABC) propensity score. Postoperative blood loss was significantly reduced in the aprotinin group [P<0.001, 95% confidence intervals (CI): 0.000.00], but postoperative red blood cell transfusion was not different between two groups (P=0.4, 95% CI: 0.3930.412). No statistical significant differences were noted in postoperative dialysis [0.39% vs 0.40%, P=0.98, OR: 0.974, 95% CI: 0.1376.944] and intra-hospital mortality (2.37% vs 1.82%, P:0.547, OR:1.306, 95% CI:0.5463.129)) and reoperations for bleeding, thrombotic, and respiratory morbidity between two groups; however, the aprotinin group had temporarily a higher rate of 1.5-fold increased creatinine (class R) in the first postoperative 72h (22.95% vs 13.93%, P<0.001, OR: 1.840, 95% CI: 1.3232.560), a longer duration of mechanical intubation [6.50 (4.5024.00)h vs 6.00 (4.5022.00)h, P=0.004, 95% CI:0.0020.005] and a 0.55% increased clinical mortality (although not statistically significant). More complex surgery had a higher rate of the increased creatinine (class R) in the first postoperative 72h (ABC level 3+4 vs level 1+2, P=0.017, OR:0.599, 95% CI:0.3920.915). The multivariate analysis showed that age (<1year), CPB >100min, and the larger amount of transfusion (14ml center dot kg1) were also important risk factors for the postoperative renal dysfunction (class R). Conclusions Except reducing postoperative bleeding, we did not find other benefits of aprotinin. However, much higher postoperative creatinine levels, longer duration of mechanical ventilation, not less postoperative RBCs transfusion, and a 0.55% increased clinical mortality (although not statistically significant) were found in the aprotinin populations.

Aprotinin Does Not Inhibit the Release of PGI2 or vWF from Cultured Human Endothelial Cells

Retrospective cohort analysis of a single dose of aprotinin use in children undergoing cardiac surgery: a single-center experience.

Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery

Effects of Methylprednisolone and Aprotinin on Phospholipase D Activity of Leukocytes in Systemic Inflammatory Response Induced by Cardiopulmonary Bypass

Effects of Preprotachykinin‐I Peptides on Hematopoietic Homeostasis: A Role for Bone Marrow Endopeptidases

EFFECT OF HEPARIN ON ACTIVATION OF PLATELET FUNCTION IN PATIENTS DURING RADIOFREQUENCY CATHETER ABLATION

Aprotinin: 1 year on

Aprotinin in high-risk isolated coronary artery bypass graft patients: a 3-year propensity matched study

Aprotinin reduces myocardial injury in the off-pump coronary artery bypass grafting]

Effects of aprotinin on short-term and long-term outcomes after coronary artery bypass grafting surgery.

Inhibition of Plasminogen Activation by a Kunitz Inhibitor, Aprotinin

Lack of efficacy of aprotinin over tranexamic acid in type A aortic dissection repair

The intra-operative use of trasylol (aprotinin) in liver transplantation

C-Reactive Protein Decreases Prostacyclin Release From Human Aortic Endothelial Cells

Aprotinin, but not ε-aminocaproic acid and tranexamic acid, exerts neuroprotection against excitotoxic injury in an in vitro neuronal cell culture model

Effects of Platelet-derived Membrane Microparticles on the Proliferation and Apoptosis of Human Umbilical Vein Endothelial Cells

Unfractionated heparin reverses aspirin inhibition of platelets during coronary artery bypass graft surgery

Use of Aprotinin versus Tranexamic Acid in Cardiac Surgery Patients with High-Risk for Excessive Bleeding (APACHE) trial: a multicentre retrospective comparative non-randomized historical study

Expression of Adhesion Molecule of Myocardial Tissue During Cardiopulmonary Bypass and Influence of Aprotinin

Assessment of aprotinin influence on periodontal clinical status and matrix metalloproteinases 1, 2 and their tissue inhibitors saliva concentrations in patients with chronic periodontitis

Heparin-like effect of a dual antiplatelet and anticoagulant (APAC) agent on red blood cell deformability and aggregation in an experimental model